Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 4/2015

01.12.2015 | Neurogenic Bladder (CR Powell, Section Editor)

The Worldwide Economic Impact of Neurogenic Bladder

verfasst von: Chandra Flack, C. R. Powell

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Costs of neurogenic bladder vary widely and depend on a number of factors including severity of disease, symptomatology, patient insurance, and devices required. Recognition of how each treatment strategy will impact the patient financially could help guide selection of treatment as well as improve compliance with the chosen regimen. We have attempted to provide an overview of long-term cost considerations for the neurogenic bladder patient. Armed with this information, the practitioner can better help the patient select a bladder care regimen that balances the desire to both minimize symptoms now and preserve urinary tract integrity for the future, yet still remain cost-effective.
Literatur
1.•
Manack A, Motsko SP, Haag‐Molkenteller C, Dmochowski RR, Goehring EL, Nguyen‐Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395–401. This large database study compares demographic characteristics and resource utilization of neurogenic bladder to the more extensively studied overactive bladder population. The authors hope to help meet unmet medical and pharmaceutical needs of these patients by better understanding the natural history of their disease with the help of a large, national database.CrossRefPubMed
2.
Ginsburg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manage Care. 2013;19:S191–6.
3.•
Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56(1):81–8. The only guideline from a major international organization specific to neurogenic bladder in the literature.CrossRefPubMed
4.
Muller N. Savings on surgical devices pale in comparison to benefits of advanced procedures. Mod Healthc. 2006;36(32):1.
5.
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.CrossRefPubMed
6.
McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis—a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn. 2008;27(3):231–7.CrossRefPubMed
7.••
Newman DK, Willson MM. Review of intermittent catheterization and current best practices. Urol Nurs. 2011;31(1):12–28. This is a comprehensive review of intermittent catheterization options for the neurogenic bladder patient. It should prove useful to the physician wishing to seek alternative treatment options for a patient who struggles to adequately manage their disease.PubMed
8.
Prieto J, Murphy CL, Moore KN, Fader M. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev. 2014;9(9), CD006008.PubMed
9.
Wyndaele J. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002;40(10):536–41.CrossRefPubMed
10.
Prieto JA, Murphy C, Moore KN, Fader MJ. Intermittent catheterisation for long‐term bladder management (abridged Cochrane review). Neurourol Urodyn. 2015.
11.
Getliffe K, Fader M, Allen C, Pinar K, Moore KN. Current evidence on intermittent catheterization: sterile single‐use catheters or clean reused catheters and the incidence of UTI. J Wound Ostomy Continence Nurs. 2007;34(3):289–96.CrossRefPubMed
12.
Polliack T, Bluvshtein V, Philo O, Ronen J, Gelernter I, Luttwak ZP, et al. Clinical and economic consequences of volume- or time-dependent intermittent catheterization in patients with spinal cord lesions and neuropathic bladder. Spinal Cord. 2005;43(10):615–9.CrossRefPubMed
13.
Prieto‐Fingerhut T, Banovac K, Lynne CM. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs. 1997;22(6):299–302.CrossRefPubMed
14.
Moy L, Wein A. Additional therapies for storage and emptying. Campbell’s urology. 2007: 2288–304.
15.
Fader M, Cottenden AM, Getliffe K. Absorbent products for light urinary incontinence in women. The Cochrane Library. 2007.
16.
Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006;50(5):1050–7.CrossRefPubMed
17.
Litwin M, Saigal C. Urologic diseases in America 2007. 2007.
18.
Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. Onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.PubMedCentralCrossRefPubMed
19.•
Hamid R, Loveman C, Millen J, Globe D, Corbell C, Colayco D, et al. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX((R))) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. PharmacoEconomics. 2015;33(4):381–93. This paper assigns a cost to the impoved benefit of onabotulinumtoxinA compared with what the authors term "best supportive care" in patients with unsatisfactory response to second line anticholinergic therapy.PubMedCentralCrossRefPubMed
20.
Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol. 2009;182(6):2799–804.CrossRefPubMed
21.
Lamb BW, Patki P, Wood S, Green J, Shah J. 10 year projection for actuarial costs for botulinum toxin injections and clam cystoplasty in patients with neurogenic and idiopathic overactive bladder. Eur Urol Suppl. 2010;9(2):61.CrossRef
22.
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.PubMed
23.
Hess M, Zhan E, Foo D, Yalla S. Bladder cancer in patients with spinal cord injury. J Spinal Cord Med. 2002;26(4):335–8.
24.
Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72.CrossRefPubMed
25.
Klausner AP, Steers WD. The neurogenic bladder: an update with management strategies for primary care physicians. Med Clin N Am. 2011;95(1):111–20.CrossRefPubMed
26.•
Al Taweel W, Seyam R. Neurogenic bladder in spinal cord injury patients. Res Rep Urol. 2015;7:85–99. This review provides an overview of the mechanism of injury behind neurogenic bladder, its impact on patient health as well as reviews current practices in the treatment of neurogenic bladder.PubMedCentralPubMed
27.
Papanicolaou S, Pons ME, Hampel C, Monz B, Quail D, Schulenburg MG, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas. 2005;52 Suppl 2:S35–47.CrossRefPubMed
Metadaten
Titel
The Worldwide Economic Impact of Neurogenic Bladder
verfasst von
Chandra Flack
C. R. Powell
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2015
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-015-0323-6

Weitere Artikel der Ausgabe 4/2015

Current Bladder Dysfunction Reports 4/2015 Zur Ausgabe

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Urologic Cancer Surveillance in Patients With Bladder Augmentation

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Functional Outcomes of Bladder Reconstruction Secondary to Trauma and Ureteral Injury

Neurogenic Bladder (CR Powell, Section Editor)

Is Postpartum Urinary Retention a Neurogenic Phenomenon?

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Robotic Surgical Approaches to Bladder Reconstruction in Adults

Geriatric Bladder Dysfunction (GM Ghoniem, Section Editor)

Lower Urinary Tract Infections in the Elderly

Neurogenic Bladder (CR Powell, Section Editor)

Sacral Neuromodulation in Children

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen